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a  b  s  t  r  a  c  t
African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var.
duboisii.  Treatment is usually extrapolated from guidelines for classical histoplasmosis,
and  includes 2–4 weeks of amphotericin B followed by a step-down maintenance therapy
with  itraconazole. Pediatric usage of posaconazole, an oral second-generation azole, remains
off-label, but recent surveys show that it is safe and well tolerated in children. We  report
a  case of disseminated African histoplasmosis in a 12-year-old boy from Guinea-Bissau.
Therapy  with amphotericin B and itraconazole led to a progressive clinical deterioration.
A  dramatic and lasting improvement was observed using posaconazole. He completed 12
months of therapy. No relapse was noted during or 3 months after treatment. We  report
that  posaconazole may be a safe and efﬁcacious drug in the salvage management ofdisseminated  AH, either in patients with disease refractory to conventional anti-fungal
therapy,  or in patients whose serious adverse effects of ﬁrst-line drugs preclude its
use.
©  2013 Elsevier Editora Ltda. Open access under CC BY-NC-ND license.Introduction
Histoplasmosis is a granulomatous disease caused by the
dimorphic  fungus Histoplasma capsulatum. There are two rec-
ognized  subspecies of this fungus pathogenic to humans,
namely Histoplasma capsulatum var. capsulatum (Hcc) and Histo-
plasma  capsulatum var. duboisii (Hcd). Classical histoplasmosis
is  caused by the former, and is endemic in North and Latin
America.  Infection by Hcd is endemic in Central and West
1Africa  and Madagascar, and is responsible for African histo-
plasmosis  (AH). All reported cases of AH in Europe are
imported from endemic areas.2
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Open access under CC BY-NC-ND license.Inhaled H. capsulatum conidia result in subclinical infection
in  the majority of exposed individuals, but disseminated dis-
ease  is not uncommon. The main clinical features of AH are
involvement of the skin, subcutaneous tissues, lymph nodes
and  bones, and rarely the lungs and other internal organs.3
Treatment of AH is usually extrapolated from the guide-
lines  of the Infectious Diseases Society of America established
for  classical histoplasmosis,4 and includes 2–4 weeks of lipo-
somal  amphotericin B followed by a step-down maintenance
therapy with oral itraconazole for at least 12 months.erraz.catarina@gmail.com (C. Ferraz), luisagvaz@netcabo.pt
Posaconazole, an oral second-generation azole, was
approved by FDA in 2006 for prophylaxis of invasive Can-
dida  and Aspergillus infections in adult immunocompromised





















































Fig. 1 – Histology from a cervical nodule – remark the
presence of numerous uninucleate thick-walled large
yeasts  Histoplasma capsulatum var. duboisii (Hcd) along
with  numerous histiocytes (HE – 400×). Below a Grocott
stain displays the thick wall of the yeasts as well as theb r a z j i n f e c t d i s .
osts. Pediatric usage of posaconazole has been described in
ome small series, and its use remains off-label. Recent sur-
eys  in which posaconazole was  used as salvage therapy show
hat  it is safe and well tolerated in children 3–17 years old.5,6
We  report the ﬁrst case of posaconazole usage as salvage
herapy in African histoplasmosis.
ase  presentation
 12-year-old African boy from Guinea-Bissau was referred to
ur hospital with a presumptive diagnosis of lymphoma. Upon
eview,  he had a 2-year history of multiple nodular formations
n  cervical, axillary, and inguinal regions, which were enlarg-
ng  with time, and were associated with cutaneous ﬁstulas.
e  had no fever, weight loss or respiratory symptoms. He had
een  treated in his home country with large-spectrum antibi-
tics  for several weeks without any clinical improvement.
On physical examination he appeared pale, but was  fully
onscious, and had normal vital signs. Cervical, axillary, and
nguinal  nodular formations were discharging a yellowish pus.
here were  no abdominal palpable masses. The other physical
xamination was  unremarkable.
Initial workup revealed anemia (hemoglobin = 7.2 g/dL),
eucocytosis (15,860/L) with neutrophilia, thrombocytosis
967,000/L), and elevated C-reactive protein (98.3 mg/L).
iver  and kidney function tests were  normal. Evaluation for
mmunologic  proﬁle did not show any evidence of immuno-
uppression and human immunodeﬁciency virus testing was
egative.  Computerized tomography (CT) of the chest revealed
 condensation in the left lower lobe with peripheral micron-
dules  and hilar calciﬁcations. Abdominal ultrasound was
ormal.
On  day 3, he started a 6-month course of anti-tuberculous
herapy due to a positive polymerase chain reaction (PCR) sam-
le  of Mycobacterium tuberculosis (Mt) in a gastric aspirate. This
nfection  was  later conﬁrmed by a positive sputum culture.
eanwhile, a cervical nodular biopsy revealed necrotic areas
long  with others containing numerous histiocytes with mul-
inucleated  giant cells, polymorphic inﬂammatory inﬁltrate,
nd  numerous uninucleate thick-walled large yeasts, budding
rom  a narrow base (Fig. 1, arrow). Based on this morphology,
 diagnosis of Hcd infection was  made and he began therapy
ith  liposomal amphotericin B (5 mg/kg/day). Histoplasmosis
as  later conﬁrmed by multiple positive swab cultures of the
xudates.  After 4 weeks of amphotericin B therapy, he was
witched  to oral itraconazole (10 mg/kg/day). At this stage, a
mall clinical improvement was  observed, with only minor
eduction  in the size of lymphadenopathies. In the following
eeks,  the patient clinical status was  rapidly deteriorating,
ith enlargement of the previously noted adenopathies, along
ith  appearance of new cutaneous ﬁstulas. A painful supra-
ubic  abdominal mass appeared, and abdominal CT identiﬁed
umerous new retroperitoneal lymphadenopathies and left
ydronephrosis due to direct compression of the ureter (Fig. 2).
mphotericin B was  restarted, with no apparent clinical ben-
ﬁt.
After  approval by our hospital’s ethics committee,
osaconazole therapy was  started, at a dosage of 400 mg
wice  daily. A dramatic and lasting improvement, both clinicalbudding  (600×).
(Fig. 3A-D) and biochemical, was observed. Imagiologic
control 2 months after introduction of posaconazole demon-
strated  resolution of hydronephrosis and only minor (1 cm)
lymphadenopathies. At day 127 of posaconazole therapy, com-
plete cicatrization of all skin lesions was achieved (Fig. 3). Our
patient  completed 12 months of therapy with posaconazole.
No  relapse was  noted during or 3 months after treatment.
Discussion
This case illustrates the many  challenges that clinicians face
when  treating conditions more  common in tropical areas.
Despite  its rarity, AH should be kept in mind as a possible diag-
nosis  in Africa-born patients who have compatible signs or
symptoms,  particularly involving the skin and lymph nodes.
The  pathogenesis of AH remains unclear. The main route of
acquisition  could be airborne contamination from the soil and,
rarely, direct inoculation.7 In this case, we could not identify
the  source of contamination. AH, as observed in our patient,
is  usually not associated with immunosuppression.7
Fungal culture remains the gold standard for diagnosis of
histoplasmosis, but is hampered by the slow growth of this
microorganism. In our patient, histological analysis revealing
granulomas and fungi within giant cells was  the key for a rapid
diagnosis.  We  should note that the observed giant cell granu-
lomatosis  could also suggest tuberculosis, but the histological
presence of yeasts, the negativity of PCR for Mycobacterium
in the histology sample, and the absence of clinical improve-
ment  with anti-tuberculous therapy suggest that tuberculosis
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Fig. 2 – Abdominal computerized tomography showing multiple retroperitoneal lymphadenopathies.
Fig. 3 – Cervical nodular formations at days 4 (A) and 22 (B) of posaconazole therapy, along with cervical (C) and inguinal (D)
regions after complete cicatrization.















































1b r a z j i n f e c t d i s .
as  not responsible for the cutaneous and abdominal masses.
uberculosis is nowadays a global emergency, responsible for
.7 million deaths/year.8 In Guinea-Bissau it is an endemic
nfection, with a prevalence of 134/100,000, as shown in a
ecent  cross-sectional survey.9 In our patient, tuberculosis
ight have contributed to AH infection, but we cannot estab-
ish  any causal relationship with these two entities.
In the previously described cases of AH, the most common
herapeutic regimens included amphotericin B and ketocona-
ole,  ﬂuconazole or itraconazole. In some of these reports,
he  disease proved fatal, either due to its natural course or
ue  to side effects, mainly associated with amphotericin B.10
osaconazole, though already successfully used as salvage
herapy  in classical histoplasmosis,11 has never been used in
efractory  AH.
Although  ﬁrm recommendations regarding use of the
ewer  azoles in histoplasmosis cannot be made, posacona-
ole  appears to be a potential valuable treatment option, even
n  comparison with established effective agents such as itra-
onazole.  In murine models infected with Histoplasma spp.,
lthough  the minimal inhibitory concentration for itracona-
ole  and posaconazole was  similar, posaconazole was  at least
0  times more  effective than itraconazole in reducing fun-
al  burden.12 Moreover, itraconazole, being a substrate for
ytochrome P450 3A4 (CYP3A4), has a greater propensity for
rug  interactions.13 This also might have contributed to itra-
onazole  failure in our patient, since he was  being treated with
he  antituberculosis drug rifampicin, an inducer of CYP3A4.14
Pharmacokinetic and efﬁcacy data for posaconazole usage
n  pediatric patients are still very limited,15 but even using
igh  doses (400 mg  twice daily), it provided a very fast, sta-
le,  and safe therapy in our patient. However, more  studies
re  needed to optimize posaconazole dosage and length of
herapy  in pediatric patients.
In  conclusion, we report that posaconazole may  be safe and
fﬁcacious  in the salvage management of disseminated AH,
ither  in patients with disease refractory to conventional anti-
ungal  therapy, or in patients whose serious adverse effects or
rug interactions of ﬁrst-line drugs preclude its use.
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